Skip to Content

The Potential for Intermediate Clinical Endpoints as Surrogates for Overall Survival

Renee Maria Saliby, a research fellow at Dana-Farber Cancer Institute, presented research exploring the use of intermediate clinical endpoints as surrogates for overall survival in patients with metastatic renal cell carcinoma receiving immune checkpoint-based regimens.

Renee Maria Saliby

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top